Anti-Smooth Muscle Myosin Heavy Chain (SM-MHC) (Leiomyosarcoma & Myoepithelial Cell Marker), Monoclonal Antibody
| Product Name | Anti-Smooth Muscle Myosin Heavy Chain (SM-MHC) (Leiomyosarcoma & Myoepithelial Cell Marker), Monoclonal Antibody |
|---|---|
| Description | Smooth muscle myosin heavy chain (SM-MHC) is a cytoplasmic structural protein, which is a major component of the contractile apparatus in smooth muscle cells. Expression of smooth muscle myosin is developmentally regulated, appearing early in smooth muscle development, and is specific for smooth muscle development. Two isoforms of smooth muscle myosin heavy chain have been identified, designated MHC-1 and MHC-2. The antibody may be useful for the study of breast tumors as the presence of an intact layer of myoepithelial cells is an important feature, which may distinguish benign breast lesions and carcinoma in situ from invasive tumors. |
| Synonyms | AAT4, Myosin heavy chain 11 (MYH11), Myosin heavy chain 11 smooth muscle, Smooth muscle myosin heavy chain 11, Myosin-11, SM1, SM2, SMHC, SMMHC |
| Host | Mouse |
| Clonality | Monoclonal |
| Clone | ID8 |
| Immunogen | Human uterus extract |
| Isotype | IgG1, kappa |
| Reactivity | Gallus, Bovine, Canine, Feline, Guinea Pig, Human, Porcine, Rabbit, Rat |
| Applications | FC, IF, IHC |
| Form | 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml. |
| Gene Id | 4629 |
| Uniprot | P35749 |
| Storage | Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required. |
| References | D.Lazard,.X. Sastre, M.G.Frid, M.A.Glukhova, J.-P. Thiery and V.E.Koteliansky. Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proc. Natl. Acad. Sci. USA, 1993, v.90: 999-1003.N.P. Wang, B.C. Wan, M. Skelly, M.G. Frid, M.A. Glukhova, V.E. Koteliansky, A.M. Gown. Antibodies to novel myoepithelium-associated proteins distinguish benign lesions and in-situ- carcinoma from invasive carcinoma of the breast. Applied Immunohistochemistry 1997;5(3):141-151 |
| Supplier | ARP |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
